FloBiotech Announces Agreement with UCLA Health® to Advance Neurodegenerative Disease Therapeutics
Summary
FloBiotech announced an agreement with UCLA Health to advance DDL-357, a small-molecule therapeutic for neurodegenerative disease. The deal includes a licensed asset and supports FloBiotech’s broader strategy around early disease mechanisms and protective biological pathways. The company highlighted preclinical data showing reduced phosphorylated tau and improved memory performance in disease models. FloBiotech plans to explore multiple neurodegenerative indications, including progressive supranuclear palsy and Alzheimer’s disease.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected